Hence, we predicted that during radiotherapy, alterations of the percentages of MDSCs are more sensitive in lung adenocarcinoma patients, while CD68+CD163+M2-like macrophages are more specific for lung squamous carcinoma patients. This evidence concerns the gene CD163 and lung adenocarcinoma.